PTS Closes out a round of 1.3M Euros of funding

Valencia, Spain, 18th October 2016 – Polypeptide Therapeutic Solutions SL (PTS) has closed out a 1.3m round of funding led by Columbus Venture Partners with the participation of new private investors, as well as existing investors. Columbus Venture Partners made this investment through the Columbus INNVIERTE Life Science fund, registered in the Spanish Securities & Exchange Commission (CNMV) under no.190.

This investment will allow PTS to position itself as a key supplier of transport systems for active ingredients based on polypeptides for the pharmaceutical and biotechnology industries. The application of its transport systems through skin in the dermatology and cosmetic industry is particularly important. The investment will allow the company to keep improving the quality of the products and technologies developed, and to take on an industrial scale production capacity.

PTS has positioned itself as a technological/scientific leader, with Dr María Jesús Vicent serving as scientific director of the laboratory´s research team, as well as head scientist of the biological and pharmacological assessment service at the Prince Felipe Research Centre.

Polypeptides are synthetic biodegradable biomaterials that constitute versatile tools for the development of new transporters of treatments. PTS has a know-how that protects the controlled synthesis of polypeptides with low polydispersity and versatile architectures on a large scale.

Damià Tormo, the founding partner of Columbus Venture Partners, has declared: “PTS has an excellent team with precise knowledge in order to provide excellence, thus it has become a benchmark in the industry for the chemical reforming of compounds. The versatility of their platforms allows them to adapt to all kinds of compounds regardless of their size or physicochemical properties”

Contact
Isabela Alcázar-CEO
ialcazar@pts-polypeptides.com

About PTS

Polypeptide Therapeutic Solutions S.L – is a company formed at the Prince Felipe Research Centre (Valencia). PTS is a CMO that has innovative technology for polypeptide synthesis, which allows it to control the synthesis process in a very close and reproducible manner, making it the only supplier capable of offering exact lengths of polypeptide chains, with narrow distribution of molecular weight, and reproducibility between batches. Further information http://pts-polymers.com/

About Columbus Venture Partners S.G.E.I.C., S.A

Columbus Venture Partners is a Spanish venture capital fund registered in the Spanish Securities & Exchange Commission (CNMV) under no.107. It provides a unique approach for investing in opportunities that are at an early stage of development and that have a lot of growth potential in the life sciences sector in Spain.